Clinical Trials Logo

Clinical Trial Summary

Diabetic patients with and without chronic cough will be included in this study. After giving their informed consent, the patients will perform a spirometry, chest X-ray at the inclusion visit. Cough will be assessed using the cough visual analog scale (VAS) and the Leicester Cough Questionnaire (LCQ). Within 60 days, the patient will perform neurophysiological tests. The neurophysiological assessment will be concluded with a skin biopsy to evaluate small fiber neuropathy. The aim of the study is to compare the proportion of small fiber neuropathy between diabetic patients with chronic cough and those without chronic cough.

Clinical Trial Description

Chronic cough is a very common entity that affects 9.6% people worldwide. Given the high number of patients with refractory cough, the concept of cough hypersensitivity syndrome (CHS) has emerged. In CHS, afferent sensory nerves may exhibit a modification of activation patterns with facilitation of encoding signals in response to irritating stimuli. Similar patterns with neuropathic pain have been described. Small fiber neuropathy has never been assessed in chronic cough. Interestingly, diabetic patients experienced cough more frequently than healthy subject. We hypothesized that small fiber neuropathy may explain chronic cough is more frequent in diabetic patients. Within 60 days after inclusion, diabetic patients with and without chronic cough will perform neurophysiological tests such as electromyography, thermotest, QSART (Quantitative Sudomotor Axon Reflex Test and Sudoscan), cardio-vascular tests to study the autonomic nervous system. No risks are expecting with these non-invasive tests. A skin biopsy to evaluate small fiber neuropathy will also be performed.After the neurophysiological tests, a consultation will be scheduled at 6 months. A cough VAS and LCQ will be used to assess cough. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03787511
Study type Interventional
Source University Hospital, Toulouse
Contact Laurent Guilleminault, MD
Phone 05-67-77-18-50
Email [email protected]
Status Recruiting
Phase N/A
Start date March 5, 2019
Completion date August 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Recruiting NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A
Completed NCT04053959 - Artificial Intelligence Assisted Insulin Titration System Phase 4
Recruiting NCT04365400 - TRIgyceride And Glucose Control With Epeleuton in Metabolic Syndrome Patients Phase 2
Recruiting NCT03130244 - Procedure for Duodenum to Ileal Diversion to Treat Type 2 Diabetes N/A
Recruiting NCT04383639 - Cocoa/Carob Polyphenols and Postprandial Changes in Type 2 Diabetes N/A
Recruiting NCT04326192 - Brown Adipose Tissue Activation by Spinal Cord Stimulation N/A
Recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02887898 - Efficacy of Automated Bolus Calculation in Type 2 Diabetes N/A
Not yet recruiting NCT02900417 - Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes N/A
Completed NCT02809365 - FreeStyle Libre- Effect on QOL in Type 2 Diabetes Patients N/A
Completed NCT02455076 - Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes Phase 4
Completed NCT02497170 - Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes N/A